Munich - Delayed Quote EUR

Sanofi SA (SNW2.MU)

47.20

-1.20

(-2.48%)

As of 8:03:27 AM GMT+2. Market Open.

Novavax to Report First-Quarter Earnings: Is a Beat in Store?

On NVAX's first-quarter earnings call, investors will likely focus on pipeline updates.

Zacks yesterday

NVAX

SNY
European Firms Fare Better Than Feared Through Early Trade Pain

(Bloomberg) -- European firms are reporting earnings significantly ahead of expectations, allowing for some relief in the market, but tariffs and the uncertain path of economic growth continue to cloud the outlook.Most Read from BloombergThe Battle Over the Fate of Detroit’s Renaissance CenterNYC Real Estate Industry Asks Judge to Block New Broker Fee LawNJ Transit Strike Would Be ‘Disaster’ for Region, Sherrill SaysIceland Plans for a More Volcanic FutureNJ Transit Urges Commuters to Work Remot

Bloomberg 2 days ago

SNY

SNYNF

SCGLF
Sanofi: Information concerning the total number of voting rights and shares - March 2025

Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation of the French stock market authority) Sanofia French société anonyme with a registered share capital of €2,452,461,656Registered office : 46, avenue de la Grande Armée - 75017 Paris - FranceRegistered at the Paris Commercial and Companies Regis

GlobeNewswire 4 days ago

SNY

SNYNF
Sanofi (ENXTPA:SAN) Announces €4 Per Share Dividend And New Compensation Committee Chair

Sanofi (ENXTPA:SAN) saw a 2.85% increase in its share price last week, coinciding with notable company updates. The pharmaceutical giant announced a dividend increase to €3.92 per share during its Annual General Meeting, likely reinforcing investor confidence. Additionally, Clotilde Delbos' appointment as Chairwoman of the Compensation Committee underscores a strategic personnel change. While the market also rose by 2.7%, Sanofi's earnings boost and dividend announcement may have added...

Simply Wall St. 5 days ago

SNY

SNYNF
Sanofi (SNY, Financials) Completes Opella Deal, Creates Consumer Health Leader

Sanofi retains 48.2% ownership and shifts focus to core biopharma business

GuruFocus.com 5 days ago

SNY
Press Release: Annual General Meeting of April 30, 2025

Annual General Meeting of April 30, 2025 Approval of the financial statements for the fiscal year 2024Distribution of a cash dividend of €3.92 per share, with payment as of May 14, 2025Board composition: renewal of four Directors and ratification of the cooptation of Jean-Paul Kress Paris, April 30, 2025. The Combined General Shareholders’ Meeting of Sanofi was held on April 30, 2025, under the chairmanship of Frédéric Oudéa. All resolutions submitted to the vote were adopted by the shareholders

GlobeNewswire 6 days ago

SNY

SNYNF
Press Release: Sanofi and CD&R close Opella transaction, create global consumer healthcare leader

Sanofi and CD&R close Opella transaction, create global consumer healthcare leader Paris, April 30, 2025. Opella today becomes an independent global leader in consumer healthcare, marking a pivotal step in Sanofi's strategy. Sanofi announces today the closing of the sale to CD&R of a 50.0% controlling stake of its consumer healthcare business Opella. Sanofi retains a significant shareholding of Opella with a 48.2% stake. Bpifrance will own a 1.8% stake in Opella and will join the Board. The tran

GlobeNewswire 6 days ago

SNY

SNYNF
Swedish Orphan Biovitrum AB (BIOVF) Q1 2025 Earnings Call Highlights: Strong Haematology Growth ...

Swedish Orphan Biovitrum AB (BIOVF) reports robust revenue growth driven by haematology, while facing challenges in immunology and strategic market expansions.

GuruFocus.com 7 days ago

SWOBY

SNY
Regeneron Stock Falls on Q1 Earnings and Sales Miss, Eylea Sales Down

REGN reports lower-than-expected Q1 results. Lead drug Eylea sales plunge in the United States due to competition. Stock down.

Zacks 7 days ago

REGN

SNY

BAYN.DE
Regeneron's first-quarter results miss on lower Eylea demand

(Reuters) -Regeneron's first-quarter results missed Wall Street estimates on Tuesday due to stiff competition for its blockbuster drug Eylea, further stoking investor worries as U.S. regulators denied approval for a more convenient version of the eye therapy. Shares of Regeneron were down nearly 8%. Regeneron has been looking to switch patients to a higher-dose version of the drug, branded as Eylea HD, to stymie the loss in market share to cheaper versions and rivals.

Reuters 7 days ago

REGN

SNY
Press Release: When every second counts: Sanofi, McLaren Racing and United Autosports join forces to raise meningitis awareness at Le Mans 24 Hours race

When every second counts: Sanofi, McLaren Racing and United Autosports join forces to raise meningitis awareness at Le Mans 24 Hours race Paris, April 29, 2025. Sanofi is proud to unveil an exciting new chapter in its mission to fight meningitis, as it expands its partnership with McLaren Racing for a powerful activation alongside United Autosports, the official racing partner of McLaren Automotive. This unique collaboration will see the Meningitis Flag — a powerful symbol of the global fight ag

GlobeNewswire 7 days ago

SNY

SNYNF
Private Equity Firms Target Defense Assets Once Seen as Toxic

(Bloomberg) -- Private equity firms are scouring for investment opportunities in European defense, chasing the once shunned sector in an effort to benefit from a historic switch to military expansion in the region.Most Read from BloombergNewsom Says California Is Now the World’s Fourth-Biggest EconomyAt Bryn Mawr, a Monumental Plaza Traces the Steps of Black HistoryNYC’s Congestion Toll Raised $159 Million in the First QuarterUS Cricket Deepens Bet on Texas With HQ Shift From CaliforniaLos Angel

Bloomberg 8 days ago

IVCGF

SNY

SNYNF
Swiss Agree to Tariff Negotiations With Trump Administration

(Bloomberg) -- Supply Lines is a daily newsletter that tracks global trade. Sign up here.Most Read from BloombergTrump Gives New York ‘One Last Chance’ to End Congestion FeeWhy Car YouTuber Matt Farah Is Fighting for Walkable CitiesBackyard Micro-Flats Aim to Ease South Africa’s Housing CrisisThe Racial Wealth Gap Is Not Just About MoneyTo Fuel Affordable Housing, This Innovation Fund Targets Predevelopment CostsSwitzerland said it’s one of 15 countries that will get “somewhat preferential treat

Bloomberg 12 days ago

SNY

SNYNF
Pharma Giant Roche Tops First-Quarter Views; Sanofi's Sales Come In Mixed

Roche beat first-quarter sales expectations Thursday, while Sanofi's sales report came in mixed. Shares were muted in premarket trades.

Investor's Business Daily 12 days ago

SNY

SNYNF
Sanofi axes development of oral TNF inhibitor as monotherapy following Phase II fail

Sanofi is also investigating balinatunfib in rheumatoid arthritis, Crohn's disease and ulcerative colitis.

Clinical Trials Arena 12 days ago

SNY
French Drugmaker Sanofi Clocks 20% Q1 Profit Growth, Forecasts Strong Rebound In Annual Profit

Sanofi SA (NASDAQ:SNY) reported Thursday a first-quarter 2025 business operating income of 2.9 billion euros ($3.06 billion), up 20.1% year over year and 18.7% in constant currency. The company reported first-quarter sales of 9.89 billion euros ($10.42 billion), beating the consensus of $9.77 billion. This was driven by launches, Dupixent, and favorable Beyfortus phasing. Sales increased 10.8% year over year and 9.7% on constant currency. U.S. sales were 4.66 billion and increased by 15.4%. The

Benzinga 12 days ago

SNY

IPH.PA
Sanofi Q1 Earnings Top Estimates, Dupixent Drives Sales Growth

SNY beats Q1 estimates for earnings, while missing the same for sales. It expects earnings growth to rebound in 2025.

Zacks 12 days ago

SNY

PFE
Sanofi stays on course amid tariff turmoil

The company reiterated its financial outlook for the year but is struggling to predict the likely impact of pharmaceutical tariffs given their “speculative” nature, its CFO told analysts.

BioPharma Dive 12 days ago

SNY
Sanofi Sales, Profit Beat Expectations on Higher Demand for Skin, Asthma Drug

The pharmaceutical company said the profit was driven by a higher gross margin and slower operating expense growth.

The Wall Street Journal 12 days ago

SNY

SNYNF
Press Release: Sanofi: strong Q1 performance and 2025 guidance confirmed

Sanofi: strong Q1 performance and 2025 guidance confirmed Paris, April 24, 2025 Q1 sales growth of 9.7% at CER1 and business EPS2 of €1.79 Pharma launches reached sales of €0.8 billion, up 43.8%, driven by ALTUVIIIODupixent sales were €3.5 billion, up 20.3%Vaccines sales were €1.3 billion, up 11.4%, driven by favorable Beyfortus phasingResearch and Development expenses reached €1.8 billion, up 6.9%Selling, general and administrative expenses were €2.2 billion, up 3.8%Business EPS was €1.79, up 1

GlobeNewswire 13 days ago

SNY

SNYNF

Performance Overview

Return	SNW2.MU	CAC 40 (^FCHI)
YTD	+1.29%	+3.84%
1-Year	+8.35%	-5.09%
3-Year	+7.41%	+22.46%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Sanofi SA (SNW2.MU)

Novavax to Report First-Quarter Earnings: Is a Beat in Store?

European Firms Fare Better Than Feared Through Early Trade Pain

Sanofi: Information concerning the total number of voting rights and shares - March 2025

Sanofi (ENXTPA:SAN) Announces €4 Per Share Dividend And New Compensation Committee Chair

Sanofi (SNY, Financials) Completes Opella Deal, Creates Consumer Health Leader

Press Release: Annual General Meeting of April 30, 2025

Press Release: Sanofi and CD&R close Opella transaction, create global consumer healthcare leader

Swedish Orphan Biovitrum AB (BIOVF) Q1 2025 Earnings Call Highlights: Strong Haematology Growth ...

Regeneron Stock Falls on Q1 Earnings and Sales Miss, Eylea Sales Down

Regeneron's first-quarter results miss on lower Eylea demand

Press Release: When every second counts: Sanofi, McLaren Racing and United Autosports join forces to raise meningitis awareness at Le Mans 24 Hours race

Private Equity Firms Target Defense Assets Once Seen as Toxic

Swiss Agree to Tariff Negotiations With Trump Administration

Pharma Giant Roche Tops First-Quarter Views; Sanofi's Sales Come In Mixed

Sanofi axes development of oral TNF inhibitor as monotherapy following Phase II fail

French Drugmaker Sanofi Clocks 20% Q1 Profit Growth, Forecasts Strong Rebound In Annual Profit

Sanofi Q1 Earnings Top Estimates, Dupixent Drives Sales Growth

Sanofi stays on course amid tariff turmoil

Sanofi Sales, Profit Beat Expectations on Higher Demand for Skin, Asthma Drug

Press Release: Sanofi: strong Q1 performance and 2025 guidance confirmed

Performance Overview